Detalhe da pesquisa
1.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler
; 28(3): 429-440, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240656
2.
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
J Neurol
; 271(2): 642-657, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906326
3.
Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations.
Stroke
; 43(12): 3196-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150651
4.
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Mult Scler Relat Disord
; 49: 102725, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33482590
5.
Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.
Lancet Neurol
; 18(10): 935-941, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401075
6.
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Mult Scler Relat Disord
; 9: 95-100, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27645352